How to Get Rezdiffra (Resmetirom) in Massachusetts

What Is Rezdiffra and Why Does It Matter for Massachusetts Patients?

Rezdiffra (resmetirom) is the first FDA-approved drug specifically indicated for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis. The FDA granted accelerated approval in March 2024 based on surrogate histological endpoints from the MAESTRO-NASH trial.

Before this approval, no pharmacotherapy carried a MASH-specific label. Massachusetts clinicians managed MASH patients with off-label agents, lifestyle modification, and referral to clinical trials at academic centers like Massachusetts General Hospital and Beth Israel Deaconess. That gap has closed. Resmetirom works as a thyroid hormone receptor-beta (THR-β) agonist, selectively activating hepatic THR-β to reduce liver fat, lower atherogenic lipoproteins, and improve fibrosis histology without systemic thyroid effects [1]. In MAESTRO-NASH, 25.9% of patients on the 80 mg dose achieved MASH resolution with no worsening of fibrosis at 52 weeks, compared to 9.7% on placebo (P<0.001) [1]. The 100 mg arm showed a 29.9% response rate. These are modest numbers in absolute terms, but they represent a first-in-class effect for a disease that previously had zero approved options.

Massachusetts has roughly 1.5 million adults with some form of fatty liver disease, according to state-level extrapolations from national NHANES prevalence data. A subset of those patients, those with confirmed MASH and fibrosis stages F1B through F3, now qualify for resmetirom [2].

Who Can Prescribe Rezdiffra in Massachusetts?

Any clinician holding a valid Massachusetts prescriptive authority license can write a Rezdiffra prescription. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs), provided they practice within their scope and have a collaborating physician agreement where state law requires one.

In practice, most initial prescriptions originate from hepatologists or gastroenterologists because the FDA label ties the indication to histological or imaging-confirmed fibrosis staging. A primary care physician can prescribe it, but the documentation burden for prior authorization (PA) typically requires specialty-level workup. The Massachusetts Board of Registration in Medicine does not impose additional restrictions on resmetirom beyond standard Schedule VI prescribing rules for legend drugs.

Telehealth prescribers are also eligible. Massachusetts enacted permanent telehealth parity legislation (Chapter 260 of the Acts of 2020), which allows clinicians to establish a patient-provider relationship via synchronous video and prescribe non-controlled medications, including resmetirom, without an in-person visit [3]. This is significant for patients in western Massachusetts or Cape Cod who may live hours from a hepatology practice.

How Telehealth Works for Rezdiffra in Massachusetts

Massachusetts law permits telehealth-initiated prescriptions for resmetirom. The process typically follows four steps: an initial video consultation, lab review, prior authorization submission, and pharmacy fulfillment.

During the telehealth visit, the prescriber reviews your medical history, confirms your MASH diagnosis, and evaluates fibrosis staging. If you already have a FibroScan (vibration-controlled transient elastography) result or a liver biopsy report, bring those records. Some telehealth platforms partner with local imaging centers in Massachusetts for FibroScan if you do not have a recent result. A FibroScan showing a liver stiffness measurement (LSM) of 7.0 kPa or higher generally correlates with fibrosis stage ≥F1B, though biopsy remains the reference standard [4].

Telehealth visits for resmetirom typically last 20 to 40 minutes. The prescriber must document the clinical rationale, confirm the fibrosis stage, and record baseline labs before submitting the prescription. Massachusetts commercial insurers and MassHealth both accept telehealth-originated prescriptions for PA purposes, as long as the clinical documentation meets the same standards as an in-person evaluation.

One practical advantage: telehealth platforms often have dedicated PA teams that handle insurer communications. This can shave days off the approval timeline compared to a solo practitioner's office managing the paperwork internally.

What Labs Are Required Before Starting Rezdiffra?

The FDA prescribing information and clinical best practices require several baseline labs before initiating resmetirom. Expect your prescriber to order the following panel:

Thyroid function: TSH and free T4. Resmetirom is a selective THR-β agonist, but the FDA label recommends checking thyroid function at baseline and periodically during treatment. Patients with uncontrolled hypothyroidism or hyperthyroidism should have thyroid disease stabilized before starting the drug [5].

Liver panel: ALT, AST, alkaline phosphatase, total bilirubin, albumin, and platelet count. These establish your baseline hepatic function and help calculate a FIB-4 index. The American Association for the Study of Liver Diseases (AASLD) recommends FIB-4 as a first-line noninvasive test for fibrosis risk stratification [6].

Lipid panel: Total cholesterol, LDL-C, HDL-C, and triglycerides. Resmetirom significantly lowers LDL-C and triglycerides. In MAESTRO-NASH, the 80 mg dose reduced LDL-C by approximately 14% and triglycerides by approximately 19% at 24 weeks [1]. Your prescriber will want a baseline to track this secondary benefit.

Comprehensive metabolic panel and CBC: Standard pre-treatment safety labs. Gallbladder-related adverse events occurred in 3.7% of resmetirom patients versus 1.8% on placebo in MAESTRO-NASH [1], so some clinicians also order a right-upper-quadrant ultrasound at baseline.

Massachusetts insurers, including MassHealth, commonly require these labs as part of the PA documentation package. Missing labs are the single most common reason for PA delays.

MassHealth and Commercial Insurance Coverage in Massachusetts

MassHealth (Massachusetts Medicaid) covers Rezdiffra with prior authorization. The PA criteria generally require documentation of a MASH diagnosis, fibrosis stage F1B through F3 confirmed by biopsy or validated noninvasive test, baseline labs, and evidence that lifestyle interventions alone have been insufficient.

Commercial plans in Massachusetts vary. Most major carriers, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan, have added Rezdiffra to their specialty formularies with PA requirements as of 2025. Tier placement differs: some plans list it as Tier 4 (specialty), while others place it on Tier 5 (specialty with higher cost-sharing). Monthly out-of-pocket costs for commercially insured patients typically range from $50 to $500 depending on plan design, deductible status, and whether the patient uses Madrigal Pharmaceuticals' copay assistance program.

Madrigal offers a copay card program for commercially insured patients that can reduce out-of-pocket costs to as low as $0 per fill for eligible patients, with a maximum annual benefit. Patients on government insurance (MassHealth, Medicare, Tricare) are not eligible for the copay card but may qualify for Madrigal's separate patient assistance program.

For Medicare Part D beneficiaries in Massachusetts, Rezdiffra coverage depends on the specific Part D plan formulary. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drug spending, which took effect in 2025, can significantly reduce the financial burden for Medicare enrollees using resmetirom [7].

Prior Authorization: What Massachusetts Insurers Require

Prior authorization is the most common bottleneck between prescription and pharmacy pickup. Here is what Massachusetts payers typically ask for:

Clinical documentation: A letter of medical necessity from the prescriber, including the MASH diagnosis (ICD-10 code K75.81), the fibrosis stage, the method used to confirm fibrosis (biopsy report or FibroScan/MRE result), and a statement that the patient has moderate-to-advanced fibrosis (F1B, F2, or F3).

Lab results: Baseline liver panel, thyroid function, lipid panel, and FIB-4 score. Some insurers also require documentation of BMI and hemoglobin A1c, since MASH frequently co-occurs with type 2 diabetes and obesity.

Treatment history: Evidence that lifestyle modifications (diet, exercise, weight management) have been attempted or are ongoing. Some payers require documentation of at least 3 to 6 months of lifestyle intervention before approving resmetirom, though this is not an FDA requirement.

Exclusion criteria: Insurers typically deny PA if the patient has decompensated cirrhosis (Child-Pugh B or C), fibrosis stage F4 (cirrhosis), or active hepatocellular carcinoma. The FDA indication is limited to fibrosis stages F1B through F3.

PA turnaround in Massachusetts averages 5 to 10 business days for commercial plans and 7 to 14 business days for MassHealth, based on industry benchmarks. If denied, patients and prescribers can file a Level 1 appeal. MassHealth requires the appeal within 30 calendar days of the denial notice. Commercial plan appeal timelines vary but are governed by Massachusetts Division of Insurance regulations.

Pharmacy Access: Specialty and 503A Options in Massachusetts

Rezdiffra is classified as a specialty medication. Most patients fill it through specialty pharmacies rather than retail chains. Several specialty pharmacies operating in Massachusetts stock resmetirom, including Accredo, CVS Specialty, and Optum Specialty Pharmacy. These pharmacies handle the coordination between the prescriber, the insurer, and the patient, often assigning a dedicated care coordinator to manage refills and PA renewals.

Massachusetts also permits 503A compounding pharmacies to dispense resmetirom. Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to compound medications based on individual patient prescriptions [8]. This pathway can be relevant for patients who need dose adjustments outside the standard 60 mg, 80 mg, and 100 mg tablet strengths, though most patients fit within the commercially available doses.

The Massachusetts Board of Registration in Pharmacy oversees 503A pharmacy licensing. Patients using a 503A pharmacy should confirm that the pharmacy holds a current Massachusetts compounding license and sources resmetirom active pharmaceutical ingredient (API) from an FDA-registered supplier.

Shipping timelines from specialty pharmacies typically run 1 to 3 business days within Massachusetts after PA approval. Patients in Boston or the eastern corridor often receive next-day delivery. 503A pharmacies may take 3 to 5 business days for compounded preparations.

Transferring a Rezdiffra Prescription to Massachusetts

If you are relocating to Massachusetts or splitting time between states, you can transfer a valid resmetirom prescription from another state. Massachusetts accepts prescription transfers under 247 CMR 9.00 (pharmacy regulations), provided the originating prescription is valid and the prescriber holds an active license in the state where the prescription was written.

The receiving Massachusetts pharmacy contacts the sending pharmacy to verify the prescription details, remaining refills, and PA status. One catch: prior authorization does not transfer between insurers. If your insurance plan changes when you move to Massachusetts, you will need a new PA under the Massachusetts plan. Your new prescriber (or the same prescriber, if licensed in MA) will need to resubmit the clinical documentation.

For patients using telehealth, the prescriber must hold a Massachusetts license to continue prescribing after you establish residency. The Interstate Medical Licensure Compact, of which Massachusetts is a member, can expedite multi-state licensing for physicians [9].

Timeline: From First Visit to First Dose

The total time from initial consultation to receiving Rezdiffra in Massachusetts typically breaks down as follows:

Week 1: Initial consultation (in-person or telehealth). Prescriber orders baseline labs and imaging if not already completed.

Weeks 1 to 2: Labs and FibroScan results return. Prescriber confirms MASH diagnosis and fibrosis stage, documents clinical rationale, and submits the prescription with PA request.

Weeks 2 to 4: PA review period. Commercial plans average 5 to 10 business days. MassHealth may take up to 14 business days. Peer-to-peer review may be requested.

Week 4 to 5: PA approved. Specialty pharmacy processes the prescription, coordinates benefits, and ships. Delivery within 1 to 3 business days.

Total elapsed time: approximately 3 to 5 weeks for most Massachusetts patients. Patients with existing hepatology records (recent biopsy or FibroScan, current labs) can compress the timeline to as few as 2 weeks. Delays most commonly occur at the PA stage or when additional documentation is requested by the insurer.

Monitoring After Starting Rezdiffra in Massachusetts

Once you begin resmetirom, your prescriber will schedule follow-up labs. The FDA label recommends monitoring thyroid function periodically [5]. Most Massachusetts hepatologists follow a monitoring schedule of liver panel and thyroid function at 3 months, then every 6 months thereafter. Lipid panels are often repeated at 3 months to quantify the LDL-C and triglyceride reductions.

Watch for gallbladder symptoms. In MAESTRO-NASH, diarrhea (25.6% vs. 16.8% placebo) and nausea (13.2% vs. 8.2% placebo) were the most common adverse events [1]. Gallbladder-related events, including cholelithiasis and cholecystitis, occurred at a higher rate with resmetirom than placebo. Report right-upper-quadrant pain, fever, or jaundice to your prescriber immediately.

Resmetirom is taken once daily with food. The FDA label specifies weight-based dosing: 80 mg for patients weighing <100 kg and 100 mg for patients weighing ≥100 kg. Do not adjust the dose without consulting your prescriber.